Clinical Trials Logo
  1. Home
  2. Stomach Neoplasms
  3. NCT05208372
  4. Details
NCT05208372 Clinical Trial

Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer

Stomach Neoplasms Clinical Trial

— CTC_ctDNA  

Official title:
Application of the Detection of Circulating Tumor Cell and Circulating Tumor DNA in the Diagnosis of Metastasis in Gastric Cancer

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05208372
Other study ID # FirstHCMU_CTC_ctDNA
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date January 31, 2024

Study information
Verified date January 2022
Source First Hospital of China Medical University
Contact Kai Li, MD
Phone 8613998245233
Email cmu1h_likai@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To investigate the value of CTCs and ctDNA in the diagnosis of metastasis in ascites/peritoneal flushing fluid and blood; To investigate the influence of laparoscopic CO2 pneumoperitoneum establishment on peritoneal and hematogenous metastasis of advanced gastric cancer; To explore the influence of the number and type of CTCs and ctDNA on metastasis and prognosis.

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date January 31, 2024
Est. primary completion date February 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: 1. Patients who sign informed consent. 2. Gastric cancer is determined by more than 2 pathologists. 3. Patients with Borrmann III/IV gastric cancer. Exclusion Criteria: 1. Patients who complicate with other malignant tumors. 2. Patients who complicate with other serious heart and lung diseases. 3. Patients who receive preoperative neoadjuvant chemotherapy.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• CTC test
Circulating tumor cells test of ascites and blood for patients with gastric cancer.
• ctDNA test
Circulating tumor DNA test of ascites and blood for patients with gastric cancer.

Locations
Country Name City State
China First Hospital of Jinzhou Medical University Jinzhou Liaoning
China The First Affiliated Hospital of China Medical University Shenyang Liaoning

Sponsors (1)
Lead Sponsor Collaborator
First Hospital of China Medical University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Quantity of CTCs To count the circulating tumor cells in ascites and blood. 1 day
Primary Classification of CTCs To classify the circulating tumor cells in ascites and blood. 1 day
Primary Expression of ctDNA To assess the expression of circulating tumor DNA in ascites and blood, including YAP1, LAMC1 and DDIT4. 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04351867 - A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer Phase 3
Recruiting NCT02887612 - ctDNA for Prediction of Relapse in Gastric Cancer
Active, not recruiting NCT02930291 - The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Active, not recruiting NCT01609309 - Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) Phase 3
Completed NCT00382720 - Docetaxel and Oxaliplatin in Gastric Cancer Phase 2
Completed NCT00375999 - Docetaxel and Epirubicin in Advanced Gastric Cancer Phase 2
Completed NCT00980382 - A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma Phase 1/Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT05033392 - PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Phase 2
Completed NCT04539769 - Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes Phase 2
Active, not recruiting NCT02930278 - The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
Active, not recruiting NCT02845986 - Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Phase 2
Completed NCT02902575 - The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy N/A
Recruiting NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Phase 3
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4